Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

HuiGene, a Shanghai Gene Editing Company, Closes $62 Million B Round

publication date: Jun 18, 2021

HuiGene Therapeutics, a Shanghai gene-editing company, closed a $62 million Series B round for its gene editing tools and drug discovery programs based on gene editing for rare diseases. Founded in 2018, HuiGene says it focuses on the CRISPER-Cas editing system, based on the Cas19 protein and targeting ssRNA to edit RNA. Because this technology does not change DNA, the company says it offers better safety than competing gene editing programs. It is carrying out R&D of gene therapies for neurodegenerative diseases, visual disorders, hearing disorders and other diseases. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China